BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in PIK3CA-Mutant Colorectal Cancer.

doi:10.1158/1535-7163.MCT-24-1096

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in PIK3CA-Mutant Colorectal Cancer.

Molecular cancer therapeutics - 2 Dec 2025

DeStefanis Rebecca A, Schmitz Alexa E, Steimle Alyssa K, Payne Susan N, Sha Gioia C, Olson Autumn M, Cornelio Alec, Lippert Anna E L, Kraus Sean G, Johnson Katherine A, Favreau Peter F, Gillette Amani, Babiarz Christopher, Miller Devon, Sprackling Carley M, Pasch Cheri A, Pritzl Stephanie, Van De Hey Dana R, Korkos Demetra P, Foley Tyler M, Yueh Alexander E, Greane Aurora L J X, Clipson Linda, Skala Melissa C, Deming Dustin A

Abstract excerpt

Targeting PIK3CA-mutant colorectal cancers with precision medicine strategies is of great clinical interest. However, resistance to single-agent PI3K pathway inhibitors has been observed across multiple clinical trials, necessitating the identification of combination therapies that overcome or prevent resistance to precision medicine strategies. Previously, our group identified that inhibition of mTORC1/2 is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Drug Synergism

Share to Mechanistic Target of Rapamycin Complex 1

Share to Mechanistic Target of Rapamycin Complex 2

Share to Proto-Oncogene Proteins c-bcl-2

Share to Quinazolines

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 40635161
DOI: 10.1158/1535-7163.MCT-24-1096
PMCID: PMC12767208

Genes

PIK3CA
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in PIK3CA-Mutant Colorectal Cancer.PMID 40635161Read ↗

Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.Semantic proximity Read ↗

mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.Semantic proximity Read ↗

A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic CancerSemantic proximity Read ↗

Copanlisib in combination with nivolumab formicrosatellite stable colorectal cancer: a phase 1/2 trial.Semantic proximity Read ↗

Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic BirinapantSemantic proximity Read ↗

Cell line models for drug discovery in PIK3CA-mutated colorectal cancers.Semantic proximity Read ↗

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.Semantic proximity Read ↗

Selective Eradication of Colon Cancer Cells Harboring PI3K and/or MAPK Pathway Mutations in 3D Culture by Combined PI3K/AKT/mTOR Pathway and MEK Inhibition.Semantic proximity Read ↗

Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.Semantic proximity Read ↗

Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA MutationsSemantic proximity Read ↗

Rational application of targeted therapeutics in mucinous colon/appendix cancers with positive predictive factors.Semantic proximity Read ↗

MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.